Marilyn J Telen

List of Publications by Year
in descending order

181 papers	7,483 citations	61984 43 h-index	58581 82 g-index
227 all docs	227 docs citations	227 times ranked	9593 citing authors

#	Article	IF	Citations
1	Clonal hematopoiesis in sickle cell disease. Journal of Clinical Investigation, 2022, 132, .	8.2	26
2	Genetic determinants of telomere length from 109,122 ancestrally diverse whole-genome sequences in TOPMed. Cell Genomics, 2022, 2, 100084.	6.5	29
3	Longitudinal study of glomerular hyperfiltration in adults with sickle cell anemia: a multicenter pooled analysis. Blood Advances, 2022, 6, 4461-4470.	5.2	5
4	Potential causal role of l-glutamine in sickle cell disease painful crises: A Mendelian randomization analysis. Blood Cells, Molecules, and Diseases, 2021, 86, 102504.	1.4	14
5	Diversity of variant alleles encoding <scp>Kidd, Duffy, and Kell</scp> antigens in individuals with sickle cell disease using whole genome sequencing data from the <scp>NHLBI TOPMed Program</scp>. Transfusion, 2021, 61, 603-616.	1.6	7
6	Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature, 2021, 590, 290-299.	27.8	1,069
7	Feasibility of and barriers to thalassemia screening in migrant populations: a cross-sectional study of Myanmar and Cambodian migrants in Thailand. BMC Public Health, 2021, 21, 1177.	2.9	2
8	Rapid decline in estimated glomerular filtration rate in sickle cell anemia: results of a multicenter pooled analysis. Haematologica, 2021, 106, 1749-1753.	3.5	11
9	Identification of optimal thalassemia screening strategies for migrant populations in Thailand using a qualitative approach. BMC Public Health, 2021, 21, 1796.	2.9	3
10	Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events?. Blood Advances, 2020, 4, 3457-3465.	5.2	14
11	Serum albumin is independently associated with higher mortality in adult sickle cell patients: Results of three independent cohorts. PLoS ONE, 2020, 15, e0237543.	2.5	3
12	Loss-of-function genomic variants highlight potential therapeutic targets for cardiovascular disease. Nature Communications, 2020, 11, 6417.	12.8	39
13	An Adaptive, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease (PRAISE). Blood, 2020, 136, 19-20.	1.4	4
14	FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease. Blood, 2020, 136, 19-20.	1.4	12
15	Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis. Blood, 2020, 136, 18-19.	1.4	9
16	Genome Wide Association Analysis of Iron Overload in the Trans-Omics for Precision Medicine (TOPMed) Sickle Cell Disease Cohorts. Blood, 2020, 136, 52-52.	1.4	1
17	Pyridoxamine: another vitamin for sickle cell disease?. Haematologica, 2020, 105, 2348-2350.	3.5	1
18	Title is missing!. , 2020, 15, e0237543.		0

#	Article	IF	Citations
19	Title is missing!. , 2020, 15, e0237543.		0
20	Title is missing!. , 2020, 15, e0237543.		0
21	Title is missing!. , 2020, 15, e0237543.		0
22	Title is missing!. , 2020, 15, e0237543.		0
23	Title is missing!. , 2020, 15, e0237543.		0
24	A multiâ€institutional comparison of younger and older adults with sickle cell disease. American Journal of Hematology, 2019, 94, E115-E117.	4.1	9
25	RNA sequencing of isolated cell populations expressing human APOL1 G2 risk variant reveals molecular correlates of sickle cell nephropathy in zebrafish podocytes. PLoS ONE, 2019, 14, e0217042.	2.5	3
26	Nitric oxide loading reduces sickle red cell adhesion and vaso-occlusion in vivo. Blood Advances, 2019, 3, 2586-2597.	5.2	9
27	Therapeutic strategies for sickle cell disease: towards a multi-agent approach. Nature Reviews Drug Discovery, 2019, 18, 139-158.	46.4	116
28	Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects. Blood, 2019, 134, 616-616.	1.4	6
29	Identification of Optimal Thalassemia Screening Strategies for Migrant Populations in Thailand: A Mixed-Methods Approach. Blood, 2019, 134, 2112-2112.	1.4	1
30	Clinical and metabolomic risk factors associated with rapid renal function decline in sickle cell disease. American Journal of Hematology, 2018, 93, 1451-1460.	4.1	28
31	A common functional PIEZO1 deletion allele associates with red blood cell density in sickle cell disease patients. American Journal of Hematology, 2018, 93, E362-E365.	4.1	15
32	Knowledge, Cultural, and Structural Barriers to Thalassemia Screening in Migrant Populations in Thailand. Blood, 2018, 132, 2228-2228.	1.4	2
33	Mechanism Underlying a Role for Factor XIII (FXIII) Polymorphism in Sickle Cell Disease-Associated Priapism. Blood, 2018, 132, 2361-2361.	1.4	0
34	Thrombospondinâ€1 gene polymorphism is associated with estimated pulmonary artery pressure in patients with sickle cell anemia. American Journal of Hematology, 2017, 92, E31-E34.	4.1	10
35	Developing new pharmacotherapeutic approaches to treating sickleâ€cell disease. ISBT Science Series, 2017, 12, 239-247.	1.1	8
36	Depression, quality of life, and medical resource utilization in sickle cell disease. Blood Advances, 2017, 1, 1983-1992.	5.2	66

#	Article	IF	Citations
37	Phase 1 Study of a Sulforaphane-Containing Broccoli Sprout Homogenate for Sickle Cell Disease. PLoS ONE, 2016, 11, e0152895.	2.5	51
38	Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. Blood, 2016, 127, 810-819.	1.4	107
39	Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cellâ€induced vasoâ€occlusion. British Journal of Haematology, 2016, 175, 935-948.	2.5	38
40	Factors Related to the Progression of Sickle Cell Disease Nephropathy. Blood, 2016, 128, 9-9.	1.4	4
41	Use of Mobile Technology to Monitor Pain and Reduce Outpatient, Emergency Department (ED), and Hospital Visits for Sickle Cell Pain Crisis. Blood, 2016, 128, 2390-2390.	1.4	0
42	GWAS Meta-Analysis of Glomerular Filtration Rate in Three Cohorts of Sickle Cell Disease Patients and In Vivo Functional Analysis Reveals Potential Nephropathy Candidate Genes. Blood, 2016, 128, 269-269.	1.4	0
43	Thrombospondin-1 Polymorphisms Are Associated with Chronic Kidney Disease in Sickle Cell Anemia. Blood, 2016, 128, 2491-2491.	1.4	0
44	Effect of FXIII Polymorphism on Formation of Heterocellular Aggregates in SCD. Blood, 2016, 128, 3648-3648.	1.4	0
45	Validation of a novel point of care testing device for sickle cell disease. BMC Medicine, 2015, 13, 225.	5.5	81
46	Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood, 2015, 125, 2656-2664.	1.4	178
47	A comprehensive joint analysis of the long and short RNA transcriptomes of human erythrocytes. BMC Genomics, 2015, 16, 952.	2.8	90
48	In vivo Modeling Implicates APOL1 in Nephropathy: Evidence for Dominant Negative Effects and Epistasis under Anemic Stress. PLoS Genetics, 2015, 11, e1005349.	3.5	45
49	Biomarkers and recent advances in the management and therapy of sickle cell disease. F1000Research, 2015, 4, 1050.	1.6	5
50	Alloimmunization in sickle cell disease: changing antibody specificities and association with chronic pain and decreased survival. Transfusion, 2015, 55, 1378-1387.	1.6	75
51	Genome-Wide Evaluation of Epistasis with APOL1 Risk Variants in Sickle Cell Disease Nephropathy. Blood, 2015, 126, 3401-3401.	1.4	0
52	Phase 1 Study of the E-Selectin Inhibitor GMI 1070 in Patients with Sickle Cell Anemia. PLoS ONE, 2014, 9, e101301.	2.5	64
53	Factors associated with survival in a contemporary adult sickle cell disease cohort. American Journal of Hematology, 2014, 89, 530-535.	4.1	235
54	An Official American Thoracic Society Clinical Practice Guideline: Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 727-740.	5.6	197

#	Article	IF	Citations
55	Cellular Adhesion and the Endothelium. Hematology/Oncology Clinics of North America, 2014, 28, 341-354.	2.2	53
56	Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis. Blood, 2014, 124, 2704-2704.	1.4	4
57	Genes Associated with Survival in Adult Sickle Cell Disease. Blood, 2014, 124, 2719-2719.	1.4	1
58	The Use of Genotyping in Transfusion Medicine. , 2014, 11, .		2
59	Effects of Sulforaphane Obtained from Broccoli Sprout Homogenate in Patients with Sickle Cell Disease (SCD). Blood, 2014, 124, 4931-4931.	1.4	0
60	Sickle Erythrocytes Target Cytotoxics to Hypoxic Tumor Microvessels and Potentiate a Tumoricidal Response. PLoS ONE, 2013, 8, e52543.	2.5	18
61	Sevuparin Reduces Adhesion Of Both Sickle Red Cells and Leukocytes To Endothelial Cells In Vitro and Inhibits Vaso-Occlusion In Vivo. Blood, 2013, 122, 182-182.	1.4	9
62	An Analysis Of The Pediatric Sub-Group From The Phase 2 Study Of GMI 1070 â€“ A Novel Agent For The Vaso-Occlusive Crisis Of Sickle Cell Anemia. Blood, 2013, 122, 2206-2206.	1.4	2
63	Prophylactic Dose Low Molecular Weight Heparin (dalteparin) For Treatment Of Vaso-Occlusive Pain Crisis In Patients With Sickle Cell Disease. Blood, 2013, 122, 2241-2241.	1.4	8
64	Effects Of GMI 1070, a Pan-Selectin Inhibitor, On Pain Intensity and Opioid Utilization In Sickle Cell Disease. Blood, 2013, 122, 775-775.	1.4	2
65	GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell Disease. Blood, 2013, 122, 776-776.	1.4	7
66	In Vivo Modeling Of Genetic Mechanisms Associated With Sickle Cell Disease Nephropathy. Blood, 2013, 122, 2224-2224.	1.4	3
67	Paradoxical Effects Of Tumor Necrosis Factor-Alpha On Endothelial Adhesion Of Stored Human Red Blood Cells. Blood, 2013, 122, 2399-2399.	1.4	0
68	Effect of Propranolol as Antiadhesive Therapy in Sickle Cell Disease. Clinical and Translational Science, 2012, 5, 437-444.	3.1	40
69	Dynamic quantitative microscopy and nanoscopy of red blood cells in sickle cell disease. Proceedings of SPIE, 2012, , .	0.8	1
70	Erythrocyte plasma membraneâ€“bound ERK1/2 activation promotes ICAM-4â€“mediated sickle red cell adhesion to endothelium. Blood, 2012, 119, 1217-1227.	1.4	61
71	Translocation of Sickle Cell Erythrocyte MicroRNAs into Plasmodium falciparum Inhibits Parasite Translation and Contributes to Malaria Resistance. Cell Host and Microbe, 2012, 12, 187-199.	11.0	272
72	Characterization of the hypercoagulable state in patients with sickle cell disease. Thrombosis Research, 2012, 130, e241-e245.	1.7	36

#	Article	IF	Citations
73	Pan-Selectin Antagonist GMI-1070 Affects Biomarkers of Adhesion, Activation and the Coagulation Cascade in Sickle Cell Adults At Steady State. Blood, 2012, 120, 87-87.	1.4	1
74	Novel Optical Signature for Sickle Cell Trait Red Blood Cells. , 2012, , .		0
75	Clinical Characteristics Associated with Survival in Adult Sickle Cell Disease. Blood, 2012, 120, 3229-3229.	1.4	4
76	Genetic and Epigenetic Regulation of the Gamma Globin Locus Is Associated with Fetal Hemoglobin Levels and Frequency of Pain in Sickle Cell Disease. Blood, 2012, 120, 3230-3230.	1.4	0
77	Restoring Endogenous Nitric Oxide in Sickle or Transfused Red Cells Ameliorates Adhesion and Vaso-Occlusion in Vivo. Blood, 2012, 120, 3251-3251.	1.4	0
78	Impaired adenosine-5â€²-triphosphate release from red blood cells promotes their adhesion to endothelial cells: A mechanism of hypoxemia after transfusion*. Critical Care Medicine, 2011, 39, 2478-2486.	0.9	63
79	MYH9 and APOL1 are both associated with sickle cell disease nephropathy. British Journal of Haematology, 2011, 155, 386-394.	2.5	139
80	Quantitative microscopy and nanoscopy of sickle red blood cells performed by wide field digital interferometry. Journal of Biomedical Optics, 2011, 16, 1.	2.6	137
81	RNA Aptamer Therapy for Vaso-Occlusion in Sickle Cell Disease. Nucleic Acid Therapeutics, 2011, 21, 275-283.	3.6	11
82	Sickle Red Blood Cell Induced Adhesion of Neutrophils to Endothelial Cells and Biologic Correlates of Leukocyte Activation. Blood, 2011, 118, 1055-1055.	1.4	1
83	Inflammatory Polymorphisms Link the Risk of Acute Chest Syndrome with Asthma in Adults with Sickle Cell Disease. Blood, 2011, 118, 1072-1072.	1.4	1
84	An Elevated Tricuspid Regurgitant Jet Velocity in Sickle Cell Disease Is Associated with Polymorphisms in Genes Impacting Innate Immunity. Blood, 2011, 118, 514-514.	1.4	0
85	Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. American Journal of Hematology, 2010, 85, 36-40.	4.1	167
86	microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood, 2010, 116, 4338-4348.	1.4	313
87	Placenta growth factor in sickle cell disease: association with hemolysis and inflammation. Blood, 2010, 115, 2014-2020.	1.4	41
88	Adherence to Hydroxyurea Therapy in Children with Sickle Cell Anemia. Journal of Pediatrics, 2010, 156, 415-419.	1.8	138
89	The Relationship of Opioid Analgesia toÂQuality of Life in an Adult Sickle Cell Population. Health Outcomes Research in Medicine, 2010, 1, e29-e37.	0.6	4
90	GMI-1070, a Pan-Selectin Inhibitor: Safety and PK In a Phase 1/2 Study In Adults with Sickle Cell Disease. Blood, 2010, 116, 1632-1632.	1.4	6

#	Article	IF	Citations
91	Initial Experience with the IMPROVE Trial-a Phase III Analgesic Trial for Hospitalized Sickle Cell Painful Episodes. Blood, 2010, 116, 2667-2667.	1.4	1
92	Hydroxyurea Induces Genome-Wide Epigenetic Changes In Sickle Cell Disease. Blood, 2010, 116, 2670-2670.	1.4	1
93	S-Nitrosylation of Rap1 and Relationship to Rap1 Activity and Disease Status In SCD. Blood, 2010, 116, 2662-2662.	1.4	0
94	Factors Associated with Heterocellular Aggregate Formation In Sickle Cell Disease. Blood, 2010, 116, 2669-2669.	1.4	0
95	Genetic Variation In MYH9 Is Associated with Sickle Cell Disease Nephropathy. Blood, 2010, 116, 1648-1648.	1.4	0
96	Atypical Activation of Plasma Membrane-Bound ERK1/2 Is Associated with Regulation of Sickle Red Cell Adhesion to Endothelium. Blood, 2010, 116, 266-266.	1.4	0
97	Anti-Inflammatory Markers Are Associated with Glomerular Filtration Rate In Adults with Sickle Cell Disease.. Blood, 2010, 116, 1652-1652.	1.4	0
98	Relationship of Soluble Adhesion Receptors to Red Cell Apoptosis In SCD.. Blood, 2010, 116, 1654-1654.	1.4	0
99	Use of a Computer Based Neurocognitive Software Program in Asymptomatic Neurologically Intact Adults with Sickle Cell Disease.. Blood, 2009, 114, 1524-1524.	1.4	1
100	Polymorphisms in TNFÎ± Are Associated with Cerebrovascular Events in Sickle Cell Disease.. Blood, 2009, 114, 1540-1540.	1.4	1
101	Genetic Polymorphisms in NEDD4L Are Associated with Pulmonary Hypertension of Sickle Cell Anemia.. Blood, 2009, 114, 2562-2562.	1.4	1
102	Effects of Hydroxyurea (HU) and Magnesium Pidolate (Mg) in Hemoglobin SC Disease (HbSC): the â€œCHAMPSâ€•Trial.. Blood, 2009, 114, 819-819.	1.4	5
103	Genome-Wide Studies in Sickle Cell Anemia Show Associations Between SNPs in the Olfactory Receptor Gene Cluster and Fetal Hemoglobin Concentration.. Blood, 2009, 114, 821-821.	1.4	2
104	In-Hospital Outcomes Among Sickle Cell Patients with Acute Chest Syndrome: Results From a National Database.. Blood, 2009, 114, 1367-1367.	1.4	0
105	Retrospective Review of the Natural History of Pulmonary Hypertension in Sickle Cell Disease Demonstrates That Progressive Enlargement of the Left Atrium Is a Strong Predictor of Death.. Blood, 2009, 114, 1529-1529.	1.4	0
106	Comparison of Thrombin Generation of Sickle Cell Patients in Microparticle Rich and Microparticle Poor Plasma Using Thrombin Generation Assay (TGA).. Blood, 2009, 114, 2557-2557.	1.4	0
107	Pulmonary hypertension associated with sickle cell disease: Clinical and laboratory endpoints and disease outcomes. American Journal of Hematology, 2008, 83, 19-25.	4.1	244
108	Lack of Duffy antigen expression is associated with organ damage in patients with sickle cell disease. Transfusion, 2008, 48, 917-924.	1.6	62

#	Article	IF	Citations
109	Î²2-Adrenergic receptor and adenylate cyclase gene polymorphisms affect sickle red cell adhesion. British Journal of Haematology, 2008, 141, 105-108.	2.5	30
110	Surgical and Obstetric Outcomes in Adults with Sickle Cell Disease. American Journal of Medicine, 2008, 121, 916-921.	1.5	48
111	Adhesion molecules and hydroxyurea in the pathophysiology of sickle cell disease. Haematologica, 2008, 93, 481-485.	3.5	47
112	Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium. Blood, 2008, 112, 3474-3483.	1.4	68
113	It really IS the red cell. Blood, 2008, 112, 459-460.	1.4	3
114	The Genomic Analysis of Erythrocyte microRNA Expression in Sickle Cell Diseases. PLoS ONE, 2008, 3, e2360.	2.5	157
115	Adherence with Hydroxyurea in Children with Sickle Cell Disease. Blood, 2008, 112, 167-167.	1.4	3
116	Hydroxyurea Therapy Increases Expression of BCAM/LU and Adhesion to Laminin in Children with Sickle Cell Disease. Blood, 2008, 112, 4806-4806.	1.4	0
117	Erythrocyte Adhesion and Phosphatidylserine Exposure in HbSC Disease: Baseline Data from the CHAMPS Study. Blood, 2008, 112, 2478-2478.	1.4	0
118	Does Treatment with Hydroxyurea and Opioids Affect Age of Death in Sickle Cell Disease Patients?. Blood, 2008, 112, 4808-4808.	1.4	28
119	6 Minute Walk Test Outcomes in Sickle Cell Disease. Blood, 2008, 112, 4788-4788.	1.4	2
120	Prolonged Survival despite High Disease Burden in Elderly (â‰¥55) Patients with Hb SS or Hb SÎ²0 Thalassemia. Blood, 2008, 112, 710-710.	1.4	0
121	Genomic Approaches to Identifying Risk for Pulmonary Artery Hypertension among Individuals with Sickle Cell Disease.. Blood, 2008, 112, 1442-1442.	1.4	0
122	Obstetric and Gynecological History in Sickle Cell Disease Females. Blood, 2008, 112, 2498-2498.	1.4	0
123	Evolution of adverse changes in stored RBCs. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 17063-17068.	7.1	572
124	Role of Adhesion Molecules and Vascular Endothelium in the Pathogenesis of Sickle Cell Disease. Hematology American Society of Hematology Education Program, 2007, 2007, 84-90.	2.5	55
125	Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. Blood, 2007, 110, 2708-2717.	1.4	101
126	Fludarabine-Based Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease with and without Renal Failure: Clinical Outcome and Pharmacokinetics. Biology of Blood and Marrow Transplantation, 2007, 13, 1422-1426.	2.0	47

#	Article	IF	Citations
127	Blocking Adhesion of Sickle Erythrocytes to Endothelial P-Selectin Using an RNA Aptamer.. Blood, 2007, 110, 147-147.	1.4	2
128	Innovative Drug Design Using RNA Aptamers for Various Anemias. Oncology & Hematology Review, 2007, 00, 55.	0.2	0
129	Exploring Childhood Risk Factors That Predict End-Organ Damage in Adults with Sickle Cell Disease: The ASH Workshop on Sickle Cell Disease. , 2007, 4, .		0
130	The Effects of Chronic Opiates Pain Therapy in Sickle Cell Anemia.. Blood, 2007, 110, 3404-3404.	1.4	0
131	The Relationship of Opiate Analgesia to Quality of Life in an Adult Sickle Cell Population.. Blood, 2007, 110, 2261-2261.	1.4	0
132	The Lutheran glycoprotein: a multifunctional adhesion receptor. Transfusion, 2006, 46, 668-677.	1.6	40
133	Effect of Single Dose In Vivo Propranolol Therapy on In Vitro Adhesion of Human SS RBC.. Blood, 2006, 108, 1234-1234.	1.4	4
134	Current Prevalence of Specific Clinical Outcomes in Adult Patients with Hb SS or Hb SÎ²0 Thalassemia.. Blood, 2006, 108, 1201-1201.	1.4	1
135	Blocking Adhesion of Sickle Erythrocytes to Endothelial Î±VÎ²3 Using RNA Aptamer.. Blood, 2006, 108, 688-688.	1.4	0
136	Role of Rap1 in promoting sickle red blood cell adhesion to laminin via BCAM/LU. Blood, 2005, 105, 3322-3329.	1.4	53
137	Erythrocyte Adhesion Receptors: Blood Group Antigens and Related Molecules. Transfusion Medicine Reviews, 2005, 19, 32-44.	2.0	70
138	Transfusion Management in Sickle Cell Disease. Hematology/Oncology Clinics of North America, 2005, 19, 803-826.	2.2	56
139	Clinical and Genetic Profiles of the Aging Sickle Cell Patient.. Blood, 2005, 106, 75-75.	1.4	5
140	Left Sided Heart Dysfunction in Sickle Cell Disease: Echocardiographic and Genetic Studies.. Blood, 2005, 106, 78-78.	1.4	1
141	Role of LW and AKAP79 in Î²-Adrenergic Receptor Signaling-Induced Sickle Red Blood Cell Adhesion.. Blood, 2005, 106, 3181-3181.	1.4	1
142	Priapism in SCD: Clinical and Genetic Correlations.. Blood, 2005, 106, 3174-3174.	1.4	0
143	Molecular interactions of B-CAM (basal-cell adhesion molecule) and laminin in epithelial skin cancer. Archives of Dermatological Research, 2004, 296, 59-66.	1.9	21
144	B-CAM/LU expression and the role of B-CAM/LU activation in binding of low- and high-density red cells to laminin in sickle cell disease. American Journal of Hematology, 2004, 75, 63-72.	4.1	32

#	Article	IF	Citations
145	Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-Î±vÎ²3 interactions. Blood, 2004, 104, 3774-3781.	1.4	135
146	Pulmonary Hypertension in SS, SC and SÎ² Thalassemia: Prevalence, Associated Clinical Syndromes, and Mortality.. Blood, 2004, 104, 1663-1663.	1.4	13
147	Genetic Polymorphisms Associated with Risk for Pulmonary Hypertension and Proteinuria in Sickle Cell Disease.. Blood, 2004, 104, 1668-1668.	1.4	6
148	Effects of Single Nucleotide Polymorphisms of the Î²2 Adrenergic Receptor and of Adenylate Cyclase on Sickle Red Cell Adhesion to Laminin.. Blood, 2004, 104, 3565-3565.	1.4	13
149	Epinephrine-Induced Sickle Red Cell Adhesion and Vaso-Occlusion In Vivo Is Inhibited by the Î²-Adrenoceptor Blocker Propranolol.. Blood, 2004, 104, 364-364.	1.4	5
150	Protein Kinases Associated with Activation of Sickle Red Blood Cell Adhesion.. Blood, 2004, 104, 3567-3567.	1.4	0
151	Paroxysmal cold hemoglobinuria and cardiopulmonary bypass. Annals of Thoracic Surgery, 2003, 75, 579-581.	1.3	11
152	Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion. Blood, 2003, 101, 3281-3287.	1.4	152
153	Red Cell Antigens as Functional Molecules and Obstacles to Transfusion. Hematology American Society of Hematology Education Program, 2002, 2002, 445-462.	2.5	17
154	Principles and problems of transfusion in sickle cell disease. Seminars in Hematology, 2001, 38, 315-323.	3.4	59
155	Principles and problems of transfusion in sickle cell disease. Seminars in Hematology, 2001, 38, 315-323.	3.4	34
156	Red blood cell surface adhesion molecules: Their possible roles in normal human physiology and disease. Seminars in Hematology, 2000, 37, 130-142.	3.4	80
157	Large-scale use of red blood cell units containing alloantibodies. Immunohematology, 2000, 16, 120-123.	0.2	3
158	Critical Factors in Basal Cell Adhesion Molecule/Lutheran-mediated Adhesion to Laminin. Journal of Biological Chemistry, 1999, 274, 728-734.	3.4	80
159	Expresion of cell adhesion molecule CD44 in primary tumors of the liver: an immunohistochemical study. Liver, 1997, 17, 17-23.	0.1	26
160	Biologic functions of blood group antigens. Current Opinion in Hematology, 1996, 3, 473-479.	2.5	15
161	D, weak D (Du), and partial D: the molecular story unfolds. Transfusion, 1996, 36, 97-100.	1.6	11
162	A Blood Group-related Polymorphism of CD44 Abolishes a Hyaluronan-binding Consensus Sequence without Preventing Hyaluronan Binding. Journal of Biological Chemistry, 1996, 271, 7147-7153.	3.4	43

#	Article	IF	Citations
163	Introduction of the term â€œpartial Dâ€• Transfusion, 1996, 36, 761-762.	1.6	4
164	Location of WESbon decay-accelerating factor. Transfusion, 1995, 35, 278-278.	1.6	13
165	Blood group antigens on complement receptor/regulatory proteins. Transfusion Medicine Reviews, 1995, 9, 20-28.	2.0	8
166	Lutheran Antigens, Lutheran Regulatory Genes, and Lutheran Regulatory Gene Targets. Blood Cell Biochemistry, 1995, , 281-297.	0.3	3
167	Identification of the Tc^b allele of the Cromer blood group gene by PCR and RFLP analysis. Immunohematology, 1995, 11, 1-4.	0.2	1
168	Expression of the cell adhesion molecule CD44 in gastric adenocarcinomas. Human Pathology, 1994, 25, 1043-1049.	2.0	66
169	Monoclonal Antibody Recognizing a Unique Rh-Related Specificity. Vox Sanguinis, 1993, 64, 231-239.	1.5	6
170	Erythrocyte webb-type glycophorin C variant lacks N-glycosylation due to an asparagine to serine substitution. American Journal of Hematology, 1991, 37, 51-52.	4.1	19
171	Phosphatidylinositol-linked red blood cell membrane proteins and blood group antigens. Immunohematology, 1991, 7, 37-39.	0.2	2
172	Relationship of In^b Antigen to Other Antigens on In(Lu)â€related p80¹. Vox Sanguinis, 1990, 58, 118-121.	1.5	10
173	Relationship of In^b Antigen to Other Antigens on In(Lu)-related p80. Vox Sanguinis, 1990, 58, 118-121.	1.5	7
174	Expression of Human Erythrocyte Membrane Protein Antigens during Erythroid Differentiation. Blood Cell Biochemistry, 1990, , 27-43.	0.3	0
175	A case report: IgG autoanti-N as a cause of severe autoimmune hemolytic anemia. Immunohematology, 1990, 6, 83-86.	0.2	5
176	CD44 â€” A molecule involved in leukocyte adherence and T-cell activation. Trends in Immunology, 1989, 10, 423-428.	7.5	536
177	Human Erythrocyte Antigens. Vox Sanguinis, 1987, 52, 236-243.	1.5	6
178	Human Erythrocyte Antigens. Vox Sanguinis, 1987, 52, 236-243.	1.5	50
179	Human medullary thymocyte p80 antigen and In(Lu)-related p80 antigen reside on the same protein. Human Immunology, 1986, 17, 311-324.	2.4	26
180	AN ANTIBODY TO HUMAN THYMIC HASSALL'S BODY EPITHELIUM RECOGNIZES A SUBSET OF BLOOD GROUP A ANTIGENS. International Journal of Immunogenetics, 1985, 12, 3-15.	1.2	8

#	Article	IF	Citations
181	Functions of Blood Group Antigens. , 0, , 241-250.		0